Document is current
Any future updates will be listed below
-
Authors
Jiang, Bin
Li, Jian
Liu, Ligen
Du, Xin
Jiang, Hao https://orcid.org/0000-0002-1182-8132
Hu, Jianda
Zeng, Xiaoxi
Sakatani, Taishi https://orcid.org/0000-0001-9585-3855
Kosako, Masanori https://orcid.org/0000-0002-4981-9450
Deng, Yaru
Ivanov, Vladimir https://orcid.org/0000-0003-1536-9313
Bondarenko, Sergey https://orcid.org/0000-0002-2446-8092
Lee Lee, Lily Wong
Khuhapinant, Archrob
Martynova, Elena
Hasabou, Nahla
An, Jamie Jung-Hee
Wang, Jianxiang https://orcid.org/0000-0001-9437-9151
-
Funding
Funding for this research was provided by:
Astellas Pharma Inc.
- License Information
-
More Information
Article History
Received: 21 August 2025
Accepted: 11 December 2025
First Online: 12 January 2026
Declarations
:
: BJ, JL, LL, XD, HJ, JD, SB, LWLL, and EM have nothing to disclose. TS reports Astellas stocks. VI reports consulting and honoraria fees for speakers’ bureaus or educational events from AbbVie, Pfizer, Novartis, Sotex, Biocad, and AlPharma. AK reports consulting and honoraria fees from Roche, Johnson & Johnson, Novartis, American Taiwan Biopharm, AstraZeneca, Dr. Reddy’s, Bristol Myers Squibb, and Apexcella; and support for attending meetings and/or travel from American Taiwan Biopharm. XZ, TS, YD, JJHA, and NH are all employees of Astellas. MK was an employee of Astellas at the time the research was conducted. JW reports participation on an advisory board for AbbVie.
: The primary analysis of this study has been previously published (https://doi.org/10.1038/s41375-024-02382-9). These results have been presented in part as an oral presentation at the European Hematology Association Congress from June 12-15, 2025, in Milan, Italy.
